CM Life Sciences, Inc. (NASDAQ:CMLF) announced this morning that its shareholders approved its combination with genomic and clinical data intelligence company Sema4 and the transaction has now been completed.
The release and an earlier 8-K filing did not disclose redemption figures, but CM Life Sciences traded above $11 through the day of its July 19 redemption deadline and so it is unlikely shareholders redeemed in large numbers, if any. The press release also noted that Sema4 expected to receive $500 million in total proceeds as a part of the deal, which was the amount the parties expected to add to the company’s balance sheet at announcement.
The combined company is now slated to begin trading its shares and warrants on the Nasdaq under the ticker symbols “SMFR” and “SMFRW” beginning Friday, July 23.
The parties initially inked the $2.1 billion deal on February 10. Sema4 is dedicated to transforming healthcare by building dynamic models of human health and defining optimal, individualized health trajectories, starting in the areas of reproductive health and oncology.
Sema4 announced earlier this month that its post-transaction Board would be joined by Jason Ryan, former CFO at Magenta Therapeutics (NASDAQ:MGTA) and Foundation Medicine. CM Life Sciences has maintained strong momentum through the down market and never traded below trust value through the slump.
All measures on CM Life Science’s ballot passed by wide margins but some received as many as 17% votes against. For a full list of proposals and vote tallies, click HERE.
ADVISORS
- Jefferies LLC is acting as sole financial advisor, lead capital markets advisor, and sole placement agent to CM Life Sciences
- Cowen and Company, LLC is also acting as a capital markets advisor to CM Life Sciences
- White & Case LLP is serving as legal advisor to CM Life Sciences
- Goldman Sachs & Co. LLC and J.P. Morgan Securities LLC are serving as financial advisors to Sema4
- Fenwick & West LLP is serving as legal advisor to Sema4
Crown PropTech (OTC:CPTKW) has entered into a definitive agreement to combine with rare earth mining firm Mkango Resources (TSX-V:MKA) at a pre-money equity value of $400 million. London-based Mkango is working to commercialize a chain of rare earth mining and refining facilities in Africa and Europe. The combined company is expected to trade on the...
At the SPAC of Dawn One of the biggest sources of uncertainty in the SPAC market in recent years has been regulatory changes, but new shifts could be in its favor. SEC Chairman Paul Atkins told CNBC yesterday that the commission would review the rules for SPACs after “rather controversial” changes to the rules passed...
McKinley Acquisition Corporation (NASDAQ:MKLYU) has filed for a $150 million SPAC to hunt for an innovative target company with an experienced financial team that has dabbled in SPACs before. The new SPAC is offering investors one right to a 1/10 share in each unit with no overfunding of the trust, but it could provide a...
At the SPAC of Dawn The rain of SPACs has continued with four expected to make their debuts during today’s trading sessions after pricing their IPOs overnight. The largest of these, EQV Ventures II (NASDAQ:EVACU), even managed an upsize, making it the largest SPAC IPO since Ares II (NYSE:AACT) pulled together $450 million in 2023....
EQV Ventures II (NASDAQ:EVACU) announced the pricing of its upsized $420 million IPO and its units are expected to begin trading on the Nasdaq under the symbol “EVACU”, Wednesday, July 2, 2025. The new SPAC plans to merge with an energy target involved in upstream exploration or production. EQV II’s management team is led by...